Related Experiment Video

Updated: Jul 6, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

New therapeutic options in gastrointestinal stromal tumors

Eytan Stein1, Olivia Aranha, Mark Agulnik

  • 1Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

Oncology (Williston Park, N.Y.)
|April 16, 2008
PubMed

Insights

Gastrointestinal stromal tumors (GIST) treatment has advanced with tyrosine kinase inhibitors like imatinib and sunitinib. Further research into novel therapies and molecular markers will continue to evolve GIST treatment paradigms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GIST) historically had a poor prognosis due to limited effective therapies.
  • GIST pathogenesis often involves activating mutations in KIT or PDGFR-alpha tyrosine kinase receptors.

Purpose of the Study:

  • To review the current treatment landscape for GIST, focusing on tyrosine kinase inhibitors.
  • To discuss the evolving role of imatinib and sunitinib in managing GIST.
  • To highlight areas for future research in GIST therapy.

Main Methods:

  • Review of current literature on GIST treatment.
  • Analysis of the efficacy of imatinib and sunitinib in unresectable, metastatic, and adjuvant settings.
  • Discussion of emerging therapeutic strategies and molecular targets.

Main Results:

  • Imatinib is the standard first-line treatment for unresectable and metastatic GIST.
  • Sunitinib is approved for imatinib-resistant or intolerant GIST patients.
  • Adjuvant imatinib shows promise in prolonging disease-free interval after surgery.

Conclusions:

  • Tyrosine kinase inhibitors have significantly improved GIST outcomes.
  • Further investigation into neoadjuvant therapy and novel agents targeting molecular markers is warranted.
  • The treatment paradigm for GIST is continuously evolving with advancements in targeted therapies.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: